advisory panel rejecting vivus' medicine. the panel's recommendation came in the last few minutes of trading. with the panel meeting, shares didn't trade. they're likely to come under pressure when trading resumes. arena pharmaceuticals comes before the advisory panel in september. this is today's chart. shares were stronger after the "new england journal of medicine" reported good results with its drug. but those gains disappeared quickly after the panel recommendation on competitor vivus. this is the one year chart. as arena's date with regulators approaches, volatility has picked up. and orexigen-- it dropped with the group, on heavy volume. it's treatment is scheduled to be considered by the advisory group in december. and that is tonight's "market focus." >> susie: blame it on tomatoes. >> susie: blame it on tomatoes. that's right tomatoes. wholesale prices fell half a percent in june, led by a huge drop in fruit and vegetable prices, especially tomatoes. the latest decline in the producer price index is fueling new worr

the advisory panel already rejected vivus' treatment. intel shares were weak all day, but dropped in the final half hour of trading. here are the last 90 sessions. just before the closing bell, the "wall street journal" reported intel appears close to buying germany's infineon technologies. that would give intel a bigger play for smartphones' semiconductors. standouts today can trace the action back to their bottom lines. telecom equipment maker alcatel lucent is close to a three-month high after better-than-expected earnings. fruit company chiquita also is close to a three-month high with improving profits in europe. auto safety systems maker federal signal fell 13%, saying near-term expectations have been tempered by the economy. and life insurer genworth was hit by disappointing growth. we saw a trio of new stocks hit the market this week. chesapeake mid-stream is a natural gas partnership. its initial price was $21. envestnet provides online investment tools for money managers. it started at $9. and rare earth miner molycorp processe

catching you up on one of those biotechs working on an sperm experimental weight loss drug, vivus ctinued falling adding to friday's losses after an fda advisory panel decided against recommending its treatment for approval. finally merger talk. today that centered around h&r bloch. since january the stock down by a third. today shares bouncing on word that another tax giant wants to talk. john hugh it put together jackson hugh it and liberty tax services. he's interested in h&r bloch. and that is tonight's market focus. <<<<<<<<<<<<<<<<<<<<<<<<<< >> susie: with worries about the economy and stock market heating up, investors have been seeking the safety of bonds. for many that means treasurerys despite the puny returns. but if you can storm a a ak more risk as some investment advisors believe corporate bonds are a better yet. we look at why you may want to consider jumping on the corporate bond boat. >> reporter: when sailing in choppy waters boaters have life vests for safety. when it comes to market volatility, investors have their own form of protection: bonds. so far this year invest